Siamab Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Siamab Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10557
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:31
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Siamab Therapeutics Inc (Siamab Therapeutics), formerly Sialix Inc, is a biopharmaceutical company that focuses on the development of novel medicines targeting cancer-specific carbohydrate antigens. Its ST1 program targets a tumor associated carbohydrate antigen present in solid tumors. Siamab Therapeutics developed a technology platform that enables the discovery of large numbers of highly specific anti-TACA (tumor associated carbohydrate antigens) antibodies to kill cancer cells and also re-engage the immune system and overcome chemo-resistance.The company develops therapies in the areas of abnormal carbohydrates, glycans, ovarian, pancreatic, prostate, colon, breast and other solid tumors. Siamab Therapeutics is headquartered in Newton, Massachusetts, the US.

Siamab Therapeutics Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Siamab Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Siamab Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Siamab Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Siamab Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Siamab Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 9
Siamab Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Siamab Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Siamab Therapeutics (Sialix) Secures USD3.21 Million in Venture Funding 11
Siamab Therapeutics Raises USD2 Million in Venture Financing 12
Siamab Therapeutics Raises USD0.5 Million in Venture Financing 13
Sialix Raises US$2.5 Million In Venture Financing 14
Sialix Raises US$4 Million In Series B Financing 15
Siamab Therapeutics Raises USD0.4 Million in Venture Financing 16
Partnerships 17
Siamab Therapeutics and Boehringer Ingelheim Enter into Discovery Agreement 17
Licensing Agreements 18
Sialix Enters Into Licensing Agreement With Momenta Pharma For Monoclonal Antibody Therapeutic Program 18
Siamab Therapeutics Inc – Key Competitors 19
Siamab Therapeutics Inc – Key Employees 20
Siamab Therapeutics Inc – Locations And Subsidiaries 21
Head Office 21
Recent Developments 22
Product News 22
04/04/2018: Siamab Therapeutics to Present New Data on its ST1 Antibody Therapeutic Program Targeting Tumor-Associated STn and STn+ Myeloid Derived Suppressor Cells at the AACR Annual Meeting 2018 22
Clinical Trials 23
May 01, 2018: Siamab Therapeutics Announces Publication of New Data on its ST1 Lead Program in the Journal Oncotarget 23
Jan 03, 2018: Siamab Therapeutics to Present New Data on its ST1 Antibody Therapeutic Program Targeting Tumor-Associated STn and MDSCs at Biotech Showcase 2018 24
Oct 30, 2017: Siamab Therapeutics Presents New Preclinical Safety Data for ST1 Antibody Therapeutics Program at the 2017 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 25
Oct 03, 2017: Siamab Therapeutics Presents New Data at AACR’s Ovarian Cancer Conference Demonstrating its Anti-STn Antibody Therapeutics Inhibit Tumor Growth in Ovarian Cancer Models 26
Apr 04, 2017: Siamab Therapeutics Presents New Preclinical Data for Its Novel Anti-STn Antibodies and Anti-STn Bispecific Antibodies at the AACR Annual Meeting 2017 27
Apr 04, 2017: Siamab Therapeutics Presents New Preclinical Data On ST-1 at the AACR Annual Meeting 2017 28
Mar 21, 2017: Siamab Therapeutics to Present New Preclinical Data for Its Novel Antibodies and Antibody Drug Candidates at the American Association for Cancer Research Annual Meeting 2017 29
Mar 08, 2017: Siamab Therapeutics Announces Publication of New Preclinical Data in the Journal mAbs Describing its Novel Monoclonal Antibody Approach to Targeting the Tumor-Associated Carbohydrate Antigen STn 30
Appendix 31
Methodology 31
About GlobalData 31
Contact Us 31
Disclaimer 31

List of Tables
Siamab Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts 2
Siamab Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Siamab Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Siamab Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Siamab Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Siamab Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 9
Siamab Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Siamab Therapeutics (Sialix) Secures USD3.21 Million in Venture Funding 11
Siamab Therapeutics Raises USD2 Million in Venture Financing 12
Siamab Therapeutics Raises USD0.5 Million in Venture Financing 13
Sialix Raises US$2.5 Million In Venture Financing 14
Sialix Raises US$4 Million In Series B Financing 15
Siamab Therapeutics Raises USD0.4 Million in Venture Financing 16
Siamab Therapeutics and Boehringer Ingelheim Enter into Discovery Agreement 17
Sialix Enters Into Licensing Agreement With Momenta Pharma For Monoclonal Antibody Therapeutic Program 18
Siamab Therapeutics Inc, Key Competitors 19
Siamab Therapeutics Inc, Key Employees 20

List of Figures
Siamab Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Siamab Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Siamab Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Siamab Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Siamab Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Siamab Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Siamab Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Siamab Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Siamab Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Siamab Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Standard Bank Group Ltd (SBK):企業の財務・戦略的SWOT分析
    Standard Bank Group Ltd (SBK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • CBR Systems Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary CBR Systems Inc (CBR), a subsidiary of AMAG Pharmaceuticals Inc, is a stem cell company that offers new born stem cells. The company provides collection, processing, and long-term cryopreservation services for newborn umbilical cord blood stem cells and cord tissue units. It offers cord bloo …
  • Noble Energy Inc (NBL):企業の財務・戦略的SWOT分析
    Noble Energy Inc (NBL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Inivata Ltd:製品パイプライン分析
    Summary Inivata Ltd (Inivata) is a clinical cancer genomics company that utilizes the precision of circulating tumor DNA analysis to improve personalized healthcare in oncology. The company uses liquid biopsy platform, to identify and characterize ctDNA through a non-invasive blood test. Its liquid …
  • Eurasian Natural Resources Corporation Ltd:企業のM&A・事業提携・投資動向
    Eurasian Natural Resources Corporation Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Eurasian Natural Resources Corporation Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detai …
  • Barton Malow Co:企業の戦略的SWOT分析
    Barton Malow Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Porto Seguro SA:企業の戦略・SWOT・財務分析
    Porto Seguro SA - Strategy, SWOT and Corporate Finance Report Summary Porto Seguro SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Xintela AB (XINT):企業の財務・戦略的SWOT分析
    Summary Xintela AB (Xintela) is a biomedical company that develops treatment for cartilage damage and brain tumors. The company’s technology includes Xinmark, a patented marker technology developed to identify and select certain types of tumor cells, which can develop into cartilage cells. It also o …
  • BESIX Group SA:企業の戦略的SWOT分析
    BESIX Group SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Humabs BioMed SA:製薬・医療:M&Aディール及び事業提携情報
    Summary Humabs BioMed SA (Humabs), a subsidiary of Vir Biotechnology Inc, is an antibody therapeutics biotechnology company that discovers and develops human monoclonal antibodies. The company’s pipeline programs include Flu A virus, ebola virus, HBV, rabies virus, JCV, dengue, and others. It develo …
  • Monteloeder S.L.:戦略・SWOT・企業財務分析
    Monteloeder S.L. - Strategy, SWOT and Corporate Finance Report Summary Monteloeder S.L. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Cyprotex Ltd-医療機器分野:企業M&A・提携分析
    Summary Cyprotex Ltd (Cyprotex), a subsidiary of Evotec AG is a provider of ADME-Tox contract research services. It provides these services to the biotechnology, pharmaceutical, cosmetics/personal care and chemical industries. The company’s core capabilities include high quality mechanistic toxicolo …
  • Veloxis Pharmaceuticals AS (VELO):製薬・医療:M&Aディール及び事業提携情報
    Summary Veloxis Pharmaceuticals A/S (Veloxis) is a specialty pharmaceutical company that identifies, develops and commercializes pharmaceutical drugs in transplantation and adjacent therapies. The company developed ENVARSUS XR (tacrolimus extended-release tablets) for the prophylaxis of organ reject …
  • Metalico Inc:企業の戦略的SWOT分析
    Metalico Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Aegion Corp (AEGN):企業の財務・戦略的SWOT分析
    Aegion Corp (AEGN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • FXI, Inc.:企業の戦略的SWOT分析
    FXI, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Th …
  • AmerisourceBergen Corp (ABC):医療機器:M&Aディール及び事業提携情報
    Summary AmerisourceBergen Corp (AmerisourceBergen) is a pharmaceutical sourcing and distribution services company. It offers a wide range of services ranging from drug distribution to manufacturer solutions including niche premium logistics services, reimbursement and pharmaceutical consulting servi …
  • Frasers Property Limited:企業の戦略・SWOT・財務情報
    Frasers Property Limited - Strategy, SWOT and Corporate Finance Report Summary Frasers Property Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • AGL Energy Ltd (AGL):企業の財務・戦略的SWOT分析
    AGL Energy Ltd (AGL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Polymetal International Plc:企業の戦略・SWOT・財務情報
    Polymetal International Plc - Strategy, SWOT and Corporate Finance Report Summary Polymetal International Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆